Health Professionals

image_print

The information here in is intended solely as a guide for registered health professionals:

We at SAABI wish to thank you in advance for your due consideration of our Nicotine Delivery Systems (ENDS).

WHY SAABI:

SAABI’s Range of Naturally Extracted Tobacco products have been developed for Adult Smokers who intend on migrating away from combustable tobacco products. By way of a dedicated step-down program.

Making the move from traditional tobacco consumption isn’t always easy. for those choosing to make the change, SAABI is here to help.

  • Saabi’s step-down program allows patients to help control their need for nicotine.
  • Pods (cartridge’s) are available in 2% Strength and 1.3% Strength and 0% No Nicotine.
  • Prescriptions enable a defined dose and duration.

The RACGP’s Supporting smoking cessation – A guide for health professionals stipulates that nicotine containing e-cigarettes may be a reasonable intervention for individuals who have failed to achieve smoking cessation with approved pharmacotherapies, but remain motivated to quit smoking and have raised e-cigarette usage with their healthcare practitioner. However, practitioners should exercise caution in deciding whether it is in the patient’s best interest to prescribe nicotine for inhalation as a smoking cessation aide.

(RACGP)

In a randomized trial, e-cigarettes were more effective at producing cessation from conventional cigarette smoking than nicotine replacement therapy (NRT),  an FDA-approved cessation medication. This trial of 886 smokers attending stop-smoking services in England compared the effectiveness of e-cigarettes versus nicotine replacement for smoking cessation. Participants were provided either an e-cigarette starter pack or nicotine replacement products of their choice for three months. All users were also provided at least four weekly behavioral support sessions. Biochemically proven cigarette abstinence rates at one year were 18.0 percent in the e-cigarette user group and 9.9 percent in the NRT group (relative risk [RR] 1.83; 95% CI 1.20-2.58). However, among those who were abstinent from cigarettes at one year, 80 percent of those in the e-cigarette group were still using e-cigarettes, compared with 9 percent of those who continued to use NRT.

UpToDate

WARNING: This product may be hazardous to health and is intended for use by adult smokers. Keep out of reach of children and pets. SAABI products are not suitable for use by: persons under the age of 18+ or 21+ Depending on your country/region, pregnant or breastfeeding women, or persons who are sensitive or allergic to nicotine, and should be used with caution by persons with or at a risk of an unstable heart condition or high blood pressure.

SAABI NZ PTY LIMITED AND ITS SUBSIDIARIES,  ATTEST NO CLAIM TO ANY THERAPEUTIC BENEFIT, IN RELATION TO ITS PRODUCTS OR SERVICES

HOW TO PRESCRIBE LIQUID VAPORISOR NICOTINE:

CONSUMER MEDICINE INFORMATION(unregistered)

Prescriptions are non-PBS and can be written by hand. If using medical software, you can create a template for computerised scripts using best practice methodologies.

BEST PRACTICE

It is recommended that Patients Prescription’s be kept in a safe place in case requested by authorities. It is a good idea to keep a photo of the prescription on a smartphone.

All prescriptions need to include:

EXAMPLE ONLY

1. Nicotine concentration:

  • (2% or 1.3% , 0% No Nic) LIQUID VAPORISOR NICOTINE

2. Number of Cartridge’s for defined period:

  • 120 Cartridge’s in 92 days

3. Number of repeats:

  • 6

 

END

Printable Patient Information Leaflet:

PRINTABLE PATIENT INFORMATION LEAFLET

For Australian Health Professionals:

 

 

If in consultation with your patient, you believe that e-cigarettes may assist your patient to stop smoking the steps to follow are:

  • Arrange their importation through SAABI NZ PTY Limited or a pharmacy who will import products for this purpose. In this case the pharmacy or the medical supply business would import vaporiser nicotine for use in an e-cigarette by a named patient on submission of a prescription.

OR:

  • Apply online to the Therapeutic Goods Administration (TGA) for an approval to supply the goods under Special Access Scheme B or authorisation as an authorised prescriber. The TGA has a dedicated web page including step-by-step instructions to making an application; prescribe e-cigarettes containing vaporiser nicotine.
  • Category B is an application pathway that can be accessed by health practitioners if the patient does not fit the Category A definition and if the therapeutic good is not authorised for supply under the SAS Category C notification pathway. Category B applications must be approved by TGA before the ‘unapproved’ product may be accessed and supplied to the patient:
  • The application must be completed in full and include three patient identifiers, the patient diagnosis and indication, product details and prescriber details.The application requires a clinical justification for the use of the product, which includes reasons why a therapeutic good currently included in the ARTG cannot be used for the treatment of the individual patient in the particular circumstance.
  • An online system was introduced to enable the electronic submission of Special Access Scheme (SAS) applications and notifications to the TGA.  This system was updated to allow the submission of Authorised Prescriber (AP) applications to the TGA. Use of this online system will reduce administrative burden on health practitioners and provide users with additional system benefits to manage their SAS applications and notifications.

TGA On Line Application:

(TGA) APPLICATION B PATHWAY

Special Access Scheme & Authorised Prescriber Scheme (SAS) (AP)

(SAS) (AP) SCHEME

Attach a copy of authorised prescriber authority OR Special Access Scheme B authority below:

For The Australian Pharmaceutical Industry:

HOW TO MAKE APPLICATION:

How to order:

  •  Australian pharmacist may dispense vaporiser nicotine for use in an e-cigarette by a named patient on submission of a prescription.

 

We at SAABI wish to thank you in advance for your due consideration of our Nicotine Delivery Systems (ENDS).

 

SAABI is delighted to announce that we have appointed Anspec Pty Ltd as our exclusive agents for the Australasian market.
Anspec are a respected wholesale supplier to the pharmaceutical industry with some unique capabilities, and will be managing the roll out of SAABI products into pharmacies throughout Australia.
This decision supports our commitment to positioning SAABI products in line with the intent of the new Australian legislation, and is consistent with our commitment to exceptional quality and ethical practice.
Our Australian customers can now discuss with their doctor their needs, and doctors can now prescribe SAABI nicotine delivery systems that can be dispensed by your local pharmacy.

 

External Links

Royal Australian College of General Practitioners (RACGP)

(RACGP)

Therapeutic Goods Administration (TGA)

(TGA)

Office of Drug Control(ODC)

(ODC)

UpToDate

UpToDate

Ministry of Health Manatu Hauora (MOHNZ)

(MOHNZ)

Contact Us:

If for any reason you require further information or require assistance you can Contact our Customer Service Team via the Contact Page:

SAABI CONECT

WWW.MYSAABI.COM

Material Safety Data Sheets: 

MDSD DEVICE

MSDS CLASSIC AMERICAN

MSDS FRESH MINT

MSDS LIGHT MAPLE

MSDS TRUE APPLE

 

 

SAABI NZ PTY LIMITED AND ITS SUBSIDIARIES,  ATTEST NO CLAIM TO ANY THERAPEUTIC BENEFIT, IN RELATION TO ITS PRODUCTS OR SERVICES

SAABI NZ PTY Limited 7855847 NZBN: 9429047848887 PO Box 210107, Laurence Stevens Drive, Auckland, 2154, New Zealand.

 

 

AGE VERIFICATION

AGE VERIFICATION